Equilenin

Identification

Name
Equilenin
Accession Number
DB03515  (EXPT01356)
Type
Small Molecule
Groups
Experimental
Description

An estrogenic steroid produced by HORSES. It has a total of five double bonds in the A- and B-ring. High concentration of equilenin is found in the URINE of pregnant mares. [PubChem]

Structure
Thumb
Synonyms
Not Available
Categories
UNII
W8FTJ17C4J
CAS number
Not Available
Weight
Average: 266.3343
Monoisotopic: 266.13067982
Chemical Formula
C18H18O2
InChI Key
PDRGHUMCVRDZLQ-WMZOPIPTSA-N
InChI
InChI=1S/C18H18O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h2-5,10,16,19H,6-9H2,1H3/t16-,18-/m0/s1
IUPAC Name
(11S,15S)-5-hydroxy-15-methyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-1(10),2(7),3,5,8-pentaen-14-one
SMILES
[H][[email protected]@]12CCC(=O)[[email protected]@]1(C)CCC1=C2C=CC2=C1C=CC(O)=C2

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
USteroid Delta-isomeraseNot AvailablePseudomonas putida
USteroid Delta-isomeraseNot AvailableComamonas testosteroni
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Equilenin is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Equilenin.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Equilenin.Approved, Experimental, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Equilenin.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Equilenin.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Equilenin.Approved, Withdrawn
AldesleukinEquilenin may decrease the antineoplastic activities of Aldesleukin.Approved
AlmasilateThe bioavailability of Equilenin can be decreased when combined with Almasilate.Approved, Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Equilenin.Experimental
AloglutamolThe bioavailability of Equilenin can be decreased when combined with Aloglutamol.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Equilenin.Experimental
AluminiumThe bioavailability of Equilenin can be decreased when combined with Aluminium.Approved
Aluminium acetoacetateThe bioavailability of Equilenin can be decreased when combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe bioavailability of Equilenin can be decreased when combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe bioavailability of Equilenin can be decreased when combined with Aluminum hydroxide.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Equilenin is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Equilenin.Approved
AmiodaroneThe serum concentration of Equilenin can be increased when it is combined with Amiodarone.Approved, Investigational
Amphotericin BEquilenin may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Equilenin.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Equilenin.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Equilenin.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Equilenin.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Equilenin.Approved, Investigational
AprepitantThe serum concentration of Equilenin can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of Equilenin can be increased when it is combined with Atazanavir.Approved, Investigational
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Equilenin.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Equilenin.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Equilenin.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Equilenin.Approved, Investigational
BCG vaccineThe risk or severity of adverse effects can be increased when Equilenin is combined with BCG vaccine.Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Equilenin.Experimental
BendroflumethiazideEquilenin may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Equilenin.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Equilenin.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Equilenin.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Equilenin.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Equilenin.Experimental
Bismuth SubcitrateThe bioavailability of Equilenin can be decreased when combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe bioavailability of Equilenin can be decreased when combined with Bismuth subnitrate.Experimental
BoceprevirThe serum concentration of Equilenin can be increased when it is combined with Boceprevir.Approved, Withdrawn
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Equilenin.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Equilenin.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Equilenin.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Equilenin.Experimental
BumetanideEquilenin may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Equilenin.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of Equilenin can be decreased when combined with Calcium Carbonate.Approved
Calcium silicateThe bioavailability of Equilenin can be decreased when combined with Calcium silicate.Experimental
Capromab pendetideEquilenin may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CarbamazepineThe serum concentration of Equilenin can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Equilenin.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Equilenin.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Equilenin.Approved, Investigational
CeritinibEquilenin may increase the hyperglycemic activities of Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Equilenin.Approved, Vet Approved
ChlorothiazideEquilenin may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Equilenin can be increased when it is combined with Chlorotrianisene.Investigational, Withdrawn
ChlorthalidoneEquilenin may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Equilenin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Equilenin.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Equilenin is combined with Cinoxacin.Approved, Investigational, Withdrawn
ClarithromycinThe serum concentration of Equilenin can be increased when it is combined with Clarithromycin.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Equilenin.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Equilenin is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
CobicistatThe serum concentration of Equilenin can be increased when it is combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Equilenin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Equilenin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated estrogensThe serum concentration of Equilenin can be increased when it is combined with Conjugated estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Equilenin.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Equilenin is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CoumaphosThe risk or severity of adverse effects can be increased when Equilenin is combined with Coumaphos.Vet Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Equilenin.Investigational
CyclopenthiazideEquilenin may increase the hypokalemic activities of Cyclopenthiazide.Experimental
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Equilenin.Investigational
DaidzeinThe serum concentration of Equilenin can be increased when it is combined with Daidzein.Experimental
DanazolEquilenin may increase the fluid retaining activities of Danazol.Approved
DarunavirThe serum concentration of Equilenin can be increased when it is combined with Darunavir.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when Equilenin is combined with Decamethonium.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Equilenin is combined with Deferasirox.Approved, Investigational
DemecariumThe risk or severity of adverse effects can be increased when Equilenin is combined with Demecarium.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Equilenin.Investigational
DichlorvosThe risk or severity of adverse effects can be increased when Equilenin is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Equilenin.Approved, Vet Approved
DienestrolThe serum concentration of Equilenin can be increased when it is combined with Dienestrol.Approved, Investigational
DiethylstilbestrolThe serum concentration of Equilenin can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Equilenin.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Equilenin.Approved
DihydrotestosteroneEquilenin may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DistigmineThe risk or severity of adverse effects can be increased when Equilenin is combined with Distigmine.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Equilenin is combined with Donepezil.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Equilenin.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Equilenin.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Equilenin.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Equilenin is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Equilenin is combined with Edrophonium.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Equilenin is combined with Enoxacin.Approved, Investigational
EnzalutamideThe serum concentration of Equilenin can be decreased when it is combined with Enzalutamide.Approved
EpimestrolThe serum concentration of Equilenin can be increased when it is combined with Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Equilenin.Approved
EquolThe serum concentration of Equilenin can be increased when it is combined with Equol.Investigational
EstradiolThe serum concentration of Equilenin can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Equilenin can be increased when it is combined with Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedThe serum concentration of Equilenin can be increased when it is combined with Estrogens, esterified.Approved
EstroneThe serum concentration of Equilenin can be increased when it is combined with Estrone.Approved
Etacrynic acidEquilenin may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Equilenin.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Equilenin.Experimental
Ethinyl EstradiolThe serum concentration of Equilenin can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Equilenin.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Equilenin.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Equilenin.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Equilenin.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Equilenin.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Equilenin.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Equilenin.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Equilenin.Approved
FenthionThe risk or severity of adverse effects can be increased when Equilenin is combined with Fenthion.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Equilenin.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Equilenin.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Equilenin.Experimental
FleroxacinThe risk or severity of adverse effects can be increased when Equilenin is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Equilenin.Approved, Withdrawn
FlumequineThe risk or severity of adverse effects can be increased when Equilenin is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Equilenin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Equilenin.Experimental
FluoxymesteroneEquilenin may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Equilenin.Approved, Investigational
FosaprepitantThe serum concentration of Equilenin can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Equilenin can be decreased when it is combined with Fosphenytoin.Approved
FurosemideEquilenin may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Equilenin is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Equilenin is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Equilenin is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Equilenin is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Equilenin is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Equilenin is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Equilenin can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Equilenin is combined with GI-5005.Investigational
GLPG-0492Equilenin may increase the fluid retaining activities of GLPG-0492.Investigational
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Equilenin.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Equilenin is combined with Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Equilenin.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Equilenin.Experimental
Hepatitis A VaccineThe risk or severity of adverse effects can be increased when Equilenin is combined with Hepatitis A Vaccine.Approved
Hepatitis B Vaccine (Recombinant)The risk or severity of adverse effects can be increased when Equilenin is combined with Hepatitis B Vaccine (Recombinant).Approved, Withdrawn
HexestrolThe serum concentration of Equilenin can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Equilenin.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Equilenin is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Equilenin.Approved, Investigational
HydrochlorothiazideEquilenin may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideEquilenin may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
HydrotalciteThe bioavailability of Equilenin can be decreased when combined with Hydrotalcite.Experimental, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Equilenin.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Equilenin.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Equilenin.Approved
IdelalisibThe serum concentration of Equilenin can be increased when it is combined with Idelalisib.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Equilenin.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of Equilenin.Approved
IndapamideEquilenin may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of Equilenin can be increased when it is combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Equilenin.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Equilenin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Equilenin.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Equilenin is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Equilenin is combined with INGN 225.Investigational
IpidacrineThe risk or severity of adverse effects can be increased when Equilenin is combined with Ipidacrine.Experimental
IsoflurophateThe risk or severity of adverse effects can be increased when Equilenin is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Equilenin.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Equilenin.Withdrawn
ItraconazoleThe serum concentration of Equilenin can be increased when it is combined with Itraconazole.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Equilenin.Experimental
KetoconazoleThe serum concentration of Equilenin can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Equilenin.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Equilenin.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Equilenin.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Equilenin is combined with Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Equilenin.Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Equilenin.Experimental
LopinavirThe serum concentration of Equilenin can be increased when it is combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Equilenin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Equilenin.Approved, Investigational
LumacaftorThe serum concentration of Equilenin can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Equilenin.Approved, Investigational
MagaldrateThe bioavailability of Equilenin can be decreased when combined with Magaldrate.Approved, Withdrawn
Magnesium HydroxideThe bioavailability of Equilenin can be decreased when combined with Magnesium Hydroxide.Approved
Magnesium oxideThe bioavailability of Equilenin can be decreased when combined with Magnesium oxide.Approved
Magnesium peroxideThe bioavailability of Equilenin can be decreased when combined with Magnesium peroxide.Experimental
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Equilenin.Approved
Magnesium silicateThe bioavailability of Equilenin can be decreased when combined with Magnesium silicate.Approved, Experimental
Magnesium TrisilicateThe bioavailability of Equilenin can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Equilenin is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Equilenin.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Equilenin.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Equilenin.Approved
MefloquineThe risk or severity of adverse effects can be increased when Equilenin is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Equilenin.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Equilenin is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Equilenin.Approved
MesteroloneEquilenin may increase the fluid retaining activities of Mesterolone.Experimental
MestranolThe serum concentration of Equilenin can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Equilenin.Investigational, Withdrawn
MethallenestrilThe serum concentration of Equilenin can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Equilenin is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideEquilenin may increase the hypokalemic activities of Methyclothiazide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Equilenin.Approved, Vet Approved
MethyltestosteroneEquilenin may increase the fluid retaining activities of Methyltestosterone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Equilenin is combined with Metoclopramide.Approved, Investigational
MetolazoneEquilenin may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of Equilenin can be decreased when used in combination with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Equilenin is combined with Minaprine.Approved
MitotaneThe serum concentration of Equilenin can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Equilenin.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Equilenin.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Equilenin.Experimental
MoxestrolThe serum concentration of Equilenin can be increased when it is combined with Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Equilenin.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Equilenin.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Equilenin.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Equilenin.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Equilenin.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Equilenin is combined with Nalidixic Acid.Approved, Investigational
NandroloneEquilenin may increase the fluid retaining activities of Nandrolone.Experimental, Investigational
Nandrolone decanoateEquilenin may increase the fluid retaining activities of Nandrolone decanoate.Approved, Illicit
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Equilenin.Approved, Vet Approved
NefazodoneThe serum concentration of Equilenin can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Equilenin can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Equilenin is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Equilenin is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Equilenin.Approved
NevirapineThe serum concentration of Equilenin can be decreased when it is combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Equilenin is combined with Nicorandil.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Equilenin.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Equilenin.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Equilenin.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Equilenin.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Equilenin is combined with Norfloxacin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Equilenin.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Equilenin.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Equilenin.Vet Approved
OxandroloneEquilenin may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Equilenin.Approved
Oxolinic acidThe risk or severity of adverse effects can be increased when Equilenin is combined with Oxolinic acid.Experimental
OxymetholoneEquilenin may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Equilenin.Approved, Withdrawn
ParaoxonThe risk or severity of adverse effects can be increased when Equilenin is combined with Paraoxon.Experimental
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Equilenin.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Equilenin.Investigational
PazufloxacinThe risk or severity of adverse effects can be increased when Equilenin is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Equilenin is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of Equilenin can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe serum concentration of Equilenin can be decreased when it is combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Equilenin.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Equilenin.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Equilenin.Approved, Investigational
PhenytoinThe serum concentration of Equilenin can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Equilenin is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Equilenin.Approved, Investigational
Pipemidic acidThe risk or severity of adverse effects can be increased when Equilenin is combined with Pipemidic acid.Experimental
PiretanideEquilenin may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Equilenin.Approved, Investigational
Piromidic acidThe risk or severity of adverse effects can be increased when Equilenin is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Equilenin.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Equilenin.Experimental
Polyestradiol phosphateThe serum concentration of Equilenin can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideEquilenin may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe serum concentration of Equilenin can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Equilenin.Experimental, Investigational
PrimidoneThe serum concentration of Equilenin can be decreased when it is combined with Primidone.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Equilenin.Experimental
PromestrieneThe serum concentration of Equilenin can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Equilenin.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Equilenin.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Equilenin.Experimental
PrulifloxacinThe risk or severity of adverse effects can be increased when Equilenin is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Equilenin.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Equilenin is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of Equilenin can be increased when it is combined with Quinestrol.Approved
QuinethazoneEquilenin may increase the hypokalemic activities of Quinethazone.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Equilenin is combined with Rabies virus inactivated antigen, A.Approved
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Equilenin.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Equilenin.Approved, Experimental, Investigational
RifabutinThe serum concentration of Equilenin can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Equilenin can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Equilenin can be decreased when it is combined with Rifapentine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Equilenin is combined with Rindopepimut.Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Equilenin is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Equilenin.Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when Equilenin is combined with Rosoxacin.Approved, Investigational
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Equilenin is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Equilenin is combined with Rubella virus vaccine.Approved
RufloxacinThe risk or severity of adverse effects can be increased when Equilenin is combined with Rufloxacin.Experimental
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Equilenin.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Equilenin.Approved, Vet Approved
Salmonella typhi ty21a live antigenThe risk or severity of adverse effects can be increased when Equilenin is combined with Salmonella typhi ty21a live antigen.Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Equilenin.Approved
SaquinavirThe serum concentration of Equilenin can be increased when it is combined with Saquinavir.Approved, Investigational
SecoisolariciresinolThe serum concentration of Equilenin can be increased when it is combined with Secoisolariciresinol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Equilenin.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Equilenin.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Equilenin.Investigational
SitafloxacinThe risk or severity of adverse effects can be increased when Equilenin is combined with Sitafloxacin.Experimental, Investigational
Sodium bicarbonateThe bioavailability of Equilenin can be decreased when combined with Sodium bicarbonate.Approved
SparfloxacinThe risk or severity of adverse effects can be increased when Equilenin is combined with Sparfloxacin.Approved, Investigational
SRP 299The risk or severity of adverse effects can be increased when Equilenin is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Equilenin.Investigational
St. John's WortThe serum concentration of Equilenin can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StanozololEquilenin may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StiripentolThe serum concentration of Equilenin can be increased when it is combined with Stiripentol.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Equilenin.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Equilenin.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Equilenin.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Equilenin.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Equilenin can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Equilenin can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Equilenin is combined with Tacrine.Investigational, Withdrawn
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Equilenin.Investigational
TecemotideThe risk or severity of adverse effects can be increased when Equilenin is combined with Tecemotide.Investigational
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Equilenin.Approved, Withdrawn
TelithromycinThe serum concentration of Equilenin can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Equilenin is combined with Temafloxacin.Withdrawn
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Equilenin.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Equilenin.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Equilenin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Equilenin.Approved
TestosteroneEquilenin may increase the fluid retaining activities of Testosterone.Approved, Investigational
Testosterone PropionateEquilenin may increase the fluid retaining activities of Testosterone Propionate.Approved, Vet Approved
TG4010The risk or severity of adverse effects can be increased when Equilenin is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Equilenin.Approved
TiboloneThe serum concentration of Equilenin can be increased when it is combined with Tibolone.Approved, Investigational
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Equilenin.Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Equilenin.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Equilenin.Approved
TorasemideEquilenin may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Equilenin.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Equilenin.Experimental
TrichlorfonThe risk or severity of adverse effects can be increased when Equilenin is combined with Trichlorfon.Vet Approved
TrichlormethiazideEquilenin may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Equilenin.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Equilenin.Approved
TromethamineThe bioavailability of Equilenin can be decreased when combined with Tromethamine.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Equilenin is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Equilenin is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Equilenin.Investigational, Withdrawn
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of adverse effects can be increased when Equilenin is combined with Zoster vaccine.Approved
VoriconazoleThe serum concentration of Equilenin can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinEquilenin may increase the anticoagulant activities of Warfarin.Approved
Yellow fever vaccineThe risk or severity of adverse effects can be increased when Equilenin is combined with Yellow fever vaccine.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Equilenin.Approved, Investigational
ZeranolThe serum concentration of Equilenin can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Equilenin.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Equilenin.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

Sigfrid Schwarz, "Equilenin derivatives, methods for producing the same and medicaments containing them." U.S. Patent US20040138194, issued July 15, 2004.

US20040138194
General References
Not Available
External Links
KEGG Compound
C14303
PubChem Compound
444865
PubChem Substance
46509080
ChemSpider
392668
BindingDB
50423545
ChEBI
34739
ChEMBL
CHEMBL225546
HET
EQU
PDB Entries
1cqs / 1gs3 / 1ogx / 1ogz / 1oh0 / 1oho / 1qjg / 1w6y / 3fzw / 3ipt
show 11 more

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0052 mg/mLALOGPS
logP4.32ALOGPS
logP4.3ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)9.78ChemAxon
pKa (Strongest Basic)-5.5ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area37.3 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity79.04 m3·mol-1ChemAxon
Polarizability30.11 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9385
Caco-2 permeable+0.8879
P-glycoprotein substrateSubstrate0.5646
P-glycoprotein inhibitor INon-inhibitor0.8781
P-glycoprotein inhibitor IINon-inhibitor0.8938
Renal organic cation transporterNon-inhibitor0.7572
CYP450 2C9 substrateNon-substrate0.7038
CYP450 2D6 substrateNon-substrate0.8963
CYP450 3A4 substrateSubstrate0.6896
CYP450 1A2 substrateInhibitor0.8458
CYP450 2C9 inhibitorNon-inhibitor0.9438
CYP450 2D6 inhibitorNon-inhibitor0.9583
CYP450 2C19 inhibitorNon-inhibitor0.909
CYP450 3A4 inhibitorNon-inhibitor0.8107
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9085
Ames testNon AMES toxic0.916
CarcinogenicityNon-carcinogens0.8941
BiodegradationNot ready biodegradable0.968
Rat acute toxicity1.7016 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8623
hERG inhibition (predictor II)Inhibitor0.528
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as estrogens and derivatives. These are steroids with a structure containing a 3-hydroxylated estrane.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Estrane steroids
Direct Parent
Estrogens and derivatives
Alternative Parents
3-hydroxy delta-7-steroids / 17-oxosteroids / Delta-7-steroids / Phenanthrols / Naphthols and derivatives / Tetralins / 1-hydroxy-2-unsubstituted benzenoids / Ketones / Organic oxides / Hydrocarbon derivatives
Substituents
Estrogen-skeleton / 3-hydroxy-delta-7-steroid / 3-hydroxysteroid / Hydroxysteroid / Oxosteroid / 17-oxosteroid / Delta-7-steroid / Phenanthrol / Phenanthrene / 2-naphthol
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
3-hydroxy steroid (CHEBI:34739) / Estrane and derivatives (C14303) / C18 steroids (estrogens) and derivatives (LMST02010007)

Targets

Kind
Protein
Organism
Pseudomonas putida
Pharmacological action
Unknown
General Function
Steroid delta-isomerase activity
Specific Function
Not Available
Gene Name
ksi
Uniprot ID
P07445
Uniprot Name
Steroid Delta-isomerase
Molecular Weight
14535.48 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Comamonas testosteroni
Pharmacological action
Unknown
General Function
Steroid delta-isomerase activity
Specific Function
Not Available
Gene Name
ksi
Uniprot ID
P00947
Uniprot Name
Steroid Delta-isomerase
Molecular Weight
13398.04 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Drug created on June 13, 2005 07:24 / Updated on December 01, 2017 15:14